Results of Allo-PBT/CD34+ Series
| Author/Reference . | No. . | Age . | High-Risk . | Device . | CD34+ Cells . | CD3+ Cells . | GVHD Prophylaxis . | G-CSF Postrans. . | Engraftment . | aGVHD III-IV (%) . | cGVHD Extensive (%) . | Median Follow-up (mos) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | ANC 0.5 . | Plat 20 . | . | . | . |
| Link et al32 | 5 | 27 | 20 | CellPro | 7.78 | 1.11 | CsA | Yes | 10 | 18 | 80 | 0 | 13 |
| 5 | 37 | 20 | CellPro | 7.56 | 1.11 | CsA-MTX | Yes | 14 | 30 | 20 | 0 | 9.6 | |
| Bensinger et al33 | 5 | 58 | 80 | CellPro | 10.17 | 1.08 | CsA | No | 13 | 11 | 60 | 66 | 7.9 |
| 11 | 48 | 91 | CellPro | 8.81 | 0.68 | CsA-MTX | No | 19 | 25 | 33.3 | 20 | 3.6 | |
| Finke et al34 | 10 | 40 | 50 | CellPro | 4.1 | 0.42 | CsA n = 9 | Yes | 10 | 16 | 0 | 0 | 4.5 |
| CsA-Pred n = 1 | |||||||||||||
| Brugger et al42 | 10 | 42 | 20 | CellPro | 3.6 | 0.53 | CsA-MTX n = 10 | NA | 14 | 19 | 0 | NA | 7.8 |
| Garcia-Conde et al43 | 7 | 57 | 57 | Isolex | 4.8 | 0.09 | CsA-Pred n = 3 | Yes | 10 | 14.5 | 0 | 0 | 5.2 |
| CsA n = 4 | |||||||||||||
| Urbano-Ispizua et al (this study) | 20 | 40 | 25 | CellPro | 2.9 | 0.42 | CsA-Pred n = 20 | No | 14 | 10 | 0 | 0 | 7.5 |
| Author/Reference . | No. . | Age . | High-Risk . | Device . | CD34+ Cells . | CD3+ Cells . | GVHD Prophylaxis . | G-CSF Postrans. . | Engraftment . | aGVHD III-IV (%) . | cGVHD Extensive (%) . | Median Follow-up (mos) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | ANC 0.5 . | Plat 20 . | . | . | . |
| Link et al32 | 5 | 27 | 20 | CellPro | 7.78 | 1.11 | CsA | Yes | 10 | 18 | 80 | 0 | 13 |
| 5 | 37 | 20 | CellPro | 7.56 | 1.11 | CsA-MTX | Yes | 14 | 30 | 20 | 0 | 9.6 | |
| Bensinger et al33 | 5 | 58 | 80 | CellPro | 10.17 | 1.08 | CsA | No | 13 | 11 | 60 | 66 | 7.9 |
| 11 | 48 | 91 | CellPro | 8.81 | 0.68 | CsA-MTX | No | 19 | 25 | 33.3 | 20 | 3.6 | |
| Finke et al34 | 10 | 40 | 50 | CellPro | 4.1 | 0.42 | CsA n = 9 | Yes | 10 | 16 | 0 | 0 | 4.5 |
| CsA-Pred n = 1 | |||||||||||||
| Brugger et al42 | 10 | 42 | 20 | CellPro | 3.6 | 0.53 | CsA-MTX n = 10 | NA | 14 | 19 | 0 | NA | 7.8 |
| Garcia-Conde et al43 | 7 | 57 | 57 | Isolex | 4.8 | 0.09 | CsA-Pred n = 3 | Yes | 10 | 14.5 | 0 | 0 | 5.2 |
| CsA n = 4 | |||||||||||||
| Urbano-Ispizua et al (this study) | 20 | 40 | 25 | CellPro | 2.9 | 0.42 | CsA-Pred n = 20 | No | 14 | 10 | 0 | 0 | 7.5 |
Abbreviations: Allo-PBT/CD34+, allogeneic peripheral blood transplantation with CD34+ positive selection; No. number of patients; High risk, % of patients at advanced disease. Age of patients, engraftment kinetics and CD34+ and CD3+ cells (10E6/kg recipient) are given as median; Absolute neutrophil count (ANC) and platelets × 10E9/L. NA, not available; aGVHD, acute GVHD, cGVHD, chronic GVHD; CsA, cyclosporine A; MTX, methotrexate; pred, prednisone.